Business Context and Reporting Period
This Form 8-K was filed by Aquinox Pharmaceuticals, Inc. on May 12, 2015. The report serves to announce the company's financial results for the three-month period ended March 31, 2015. The detailed results are contained in a press release attached as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), the text of which is not included in the input source.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended March 31, 2015.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risks, contingencies, or unusual items. The document explicitly states that the information is being furnished but shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing the attached Exhibit 99.1 (Press Release), as they are absent from the 8-K body text.
- Confirm the company name discrepancy: The request metadata lists "Neurogene Inc.", but the filing is for Aquinox Pharmaceuticals, Inc.
- Note that the financial data in this report is not incorporated by reference into other SEC filings under the Securities Act of 1933 or the Exchange Act.